[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360236-105":59,"doc-detail-360236-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","study-protocol-for-the-effect-of-intraoperative-subanaesthetic-dose-esketamine-a-multicentre-prospective-randomised-controlled-trial","Study protocol for the effect of intraoperative subanaesthetic dose esketamine - A multicentre, prospective, randomised controlled trial","","This multicentre, prospective, randomised, triple-blind, placebo-controlled trial evaluates whether a single intraoperative subanaesthetic dose of esketamine, added to antidepressant therapy, reduces postoperative depressive symptoms in women with breast cancer. The study will enrol 824 participants aged 18–80 undergoing surgery for stage I–III disease and will measure depressive outcomes at postoperative day 30 using HADS Depression (score ≥8). Primary analysis applies a generalised linear mixed model with a logit link on an intention-to-treat basis; ethics approval and dissemination plans are included.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/study-protocol-for-the-effect-of-intraoperative-subanaesthetic-dose-esketamine-a-multicentre-prospective-randomised-controlled-trial/360236/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/study-protocol-for-the-effect-of-intraoperative-subanaesthetic-dose-esketamine-a-multicentre-prospective-randomised-controlled-trial/360236.png","ImageObject",300,407,{"name":92,"@type":93},"Cart","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of this trial protocol?","Question",{"text":112,"@type":113},"To determine whether a single intraoperative subanaesthetic dose of esketamine improves postoperative depressive outcomes at postoperative day 30 in patients with breast cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How will participants be assigned and what intervention will they receive?",{"text":117,"@type":113},"Women aged 18–80 with stage I–III breast cancer will be randomised 1:1 to receive 0.2 mg/kg esketamine or an equivalent volume of normal saline after anaesthesia induction and before surgical incision.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcome measures are used and when are they assessed?",{"text":121,"@type":113},"The primary outcome is the incidence of depressive symptoms at postoperative day 30, assessed with the Hospital Anxiety and Depression Scale Depression (score ≥8). Secondary outcomes include acute and chronic pain and anxious symptoms.",{"name":123,"@type":110,"acceptedAnswer":124},"What design features are intended to reduce bias, and what limitations are acknowledged?",{"text":125,"@type":113},"The protocol uses a rigorous multicentre, triple-blind, placebo-controlled randomised design with stratified block randomisation and allocation concealment to minimise selection and performance bias. It acknowledges risks to blinding from adverse events and potential measurement/attrition bias from telephone-based follow-up.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},360236,1790192836,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":46,"preview_page_count":19,"preview_urls":148},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Open access Protocol  \n Study protocol for the effect of  \nintraoperative subanaesthetic doseesketamine on the incidence of postoperative depressive symptoms inpatients with breast cancer: amulticentre, prospective, randomised controlled trial  \nZi-Yi Li,1 Jie Wang,1 Jia-Shuo Yang,1 Xin Xu,1 Fei Wang,2 Hui-Xian Li,1 Hui Zheng,1 Yi Fang,3 Shuang Ma,4 Tao Yan  1  \nTo cite: Li Z-Y, Wang J, Yang JS, et al. Study protocol for the effect of intraoperative subanaesthetic doseesketamine on the incidence of postoperative depressive symptoms in patients with breast cancer: a multicentre, prospective, randomised controlled trial. BMJ Open 2026;16:e119291 . doi:10 . 1136/ bmjopen-2026-119291  \n► Prepublication history for this paper is available online. To view these files, please visit the journal online ([https://doi](https://doi). org/10 . 1136/bmjopen-2026- 119291) .  \nZ-YL, JW and J-SY contributed equally.  \nZ-YL, JW and J-SY are joint first authors.  \nReceived 07 March 2026 Accepted 12 May 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Tao Yan; [blizzardyt@163.com](blizzardyt@163.com),  \nDr Shuang Ma; 1025085193@qq.com and Dr Yi Fang; [fangyi@cicams.ac.cn](fangyi@cicams.ac.cn)  \nABSTRACT  \nIntroduction Postoperative depressive symptoms are common after breast cancer surgery and can adversely affect recovery and quality of life. This multicentre  \ntrial aims to determine whether a single intraoperative subanaesthetic dose of esketamine, as an adjunct to antidepressant therapy, improves postoperative depressive outcomes at postoperative day (POD) 30.  \nMethods and analysis This multicentre, prospective, randomised, triple-blind, placebo-controlled trial will enrol 824 women aged 18–80 years with stage I–III breast cancer (American Society of Anesthesiologists physical status I–III) who are scheduled to undergo surgery. Participants will be randomised 1:1 to receive 0.2 mg/ kg esketamine or an equivalent volume of normal saline after anaesthesia induction and before surgical incision. The primary outcome is the incidence of depressive symptoms at POD 30, assessed using the Hospital Anxiety and Depression Scale Depression (score ≥8) . Secondary outcomes include acute and chronic pain, and anxious symptoms, etc. Primary analysis will use a generalised linear mixed model with a logit link on an intention-to-treat basis.  \nEthics and dissemination The study protocol has been formally approved by the institutional ethics committee of the National Cancer Center (Approval No.25/483-5429) . Written informed consent will be obtained from all participants prior to enrolment. Results will be disseminated through peer-reviewed journals and international scientific conferences.  \nTrial registration number ChiCTR2600117573 .  \nINTRODUCTION  \nBreast cancer is among the most common malignancies among women worldwide. According to cancer statistics, breast cancer ranks among the most prevalent malignancies worldwide, accounting for 24.5% of all  \nSTRENGTHS AND LIMITATIONS OF THIS STUDY   \n⇒ A rigorous multicentre, triple-blind, placebocontrolled randomised design with stratified block randomisation and allocation concealment minimises selection and performance bias, ensuring highquality evidence generation.  \n⇒ Long-term follow-up (up to 180 days post-surgery) and comprehensive outcome assessment (including depressive/anxiety symptoms, acute/chronic pain, oncological outcomes and adverse events) characterise symptom trajectories and the full safety/efficacy of the intervention.  \n⇒ This protocol employs a strictly targeted perioperative preventive strategy, fundamentally distinct from reactive early-treatment paradigms. By administering a single 0.2 mg/kg dose of esketamine prior to surgical incision, the intervention pre-emptively blocks stress-induced neuroinflammation at ","cbCailepjmChgyfp","https://ap.wps.com/l/cbCailepjmChgyfp","pdf",585516,"English","# Abstract\n## Methods and analysis\n## Ethics and dissemination\n# Introduction\n## Background on breast cancer and postoperative depression\n# Strengths and limitations of this study","[{\"question\":\"What is the main objective of this trial protocol?\",\"answer\":\"To determine whether a single intraoperative subanaesthetic dose of esketamine improves postoperative depressive outcomes at postoperative day 30 in patients with breast cancer.\"},{\"question\":\"How will participants be assigned and what intervention will they receive?\",\"answer\":\"Women aged 18–80 with stage I–III breast cancer will be randomised 1:1 to receive 0.2 mg/kg esketamine or an equivalent volume of normal saline after anaesthesia induction and before surgical incision.\"},{\"question\":\"What outcome measures are used and when are they assessed?\",\"answer\":\"The primary outcome is the incidence of depressive symptoms at postoperative day 30, assessed with the Hospital Anxiety and Depression Scale Depression (score ≥8). Secondary outcomes include acute and chronic pain and anxious symptoms.\"},{\"question\":\"What design features are intended to reduce bias, and what limitations are acknowledged?\",\"answer\":\"The protocol uses a rigorous multicentre, triple-blind, placebo-controlled randomised design with stratified block randomisation and allocation concealment to minimise selection and performance bias. It acknowledges risks to blinding from adverse events and potential measurement/attrition bias from telephone-based follow-up.\"}]","Study protocol for the effect of intraoperative subanaesthetic dose esketamine - A multicentre, prospective, randomised controlled trial | PDF",1790139171,[149,153,157,161],{"page_no":8,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/affeff5f26df9f5b143ecff6d1ecbe4a.webp",983,1310,{"page_no":14,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6aa239a71a1766f4ff6f705ac237ae5.webp",982,1309,{"page_no":81,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/135abaf032d71de618baa862bf72f301.webp",981,1308,{"page_no":19,"url":162,"width":163,"height":164},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/91b4ae5ed2cada51dc83bbf230798898.webp",980,1306]